hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06324981 id: 22-2097 id: 1UG3HL168504 type: NIH link: https://reporter.nih.gov/quickSearch/1UG3HL168504 briefTitle: Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors overallStatus: RECRUITING date: 2024-02-26 date: 2028-02 date: 2028-06 date: 2024-03-22 date: 2024-03-22 name: University of Colorado, Denver class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The goal of our pragmatic clinical trial is to compare how well three different strategies might do to reduce risk factors for cardiovascular disease in patients experiencing health disparities. The three different strategies are: 1) text messages, 2) interactive chatbot messages, and 3) chatbot messages with proactive pharmacist support. To measure cardiovascular risk factors, the investigators are using the American Heart Association's Life's Essential 8 (LE8) factors-blood glucose, cholesterol, blood pressure, physical activity, body mass index, diet, and smoking.
The results might help researchers and health care systems find the best ways to involve patients with health disparities to managing their chronic cardiovascular disease. conditions: Cardiovascular Diseases conditions: Lifestyle Factors studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 2100 type: ESTIMATED name: Generic text messages name: Interactive AI chatbot text messaging name: Proactive pharmacist support measure: Change in Life's Essential 8 risk score measure: Blood pressure (Individual Life's Essential 8 components) measure: Total cholesterol (Individual Life's Essential 8 components) measure: Blood sugar (Individual Life's Essential 8 components) measure: Body Mass Index (Individual Life's Essential 8 components) measure: Physical activity (Individual Life's Essential 8 components) measure: Sleep (Individual Life's Essential 8 components) measure: Smoking habits (Individual Life's Essential 8 components) measure: Health diet pattern (Individual Life's Essential 8 components) measure: Self-Efficacy for Managing Chronic Diseases measure: Number of medication refill gaps (Medication adherence) measure: Length of refill gaps (Medication adherence) measure: Clinic events measure: Risk Score for Recurrent Coronary Heart Disease, Framingham Risk Score measure: Risk Score for Coronary Heart Disease (2-year risk) - First Event, Framingham Risk Score measure: Rate of routine clinical visits and/or other procedures associated with the clinical condition measure: Cost sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Denver Health status: RECRUITING city: Denver state: Colorado zip: 80204 country: United States name: Pamela Peterson, MD MPH role: CONTACT email: pamela.peterson@dhha.org lat: 39.73915 lon: -104.9847 facility: Salud Family Health Centers status: NOT_YET_RECRUITING city: Fort Lupton state: Colorado zip: 80621 country: United States name: Emily Kosirog, PharmD role: CONTACT email: ekosirog@saludclinic.org lat: 40.08471 lon: -104.81303 facility: STRIDE Community Health Centers status: NOT_YET_RECRUITING city: Wheat Ridge state: Colorado zip: 80033 country: United States name: Danielle Montoya, PharmD role: CONTACT email: danielle.montoya@stridechc.org lat: 39.7661 lon: -105.07721 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-11 uploadDate: 2023-12-04T16:49 filename: Prot_000.pdf size: 325640 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-02-26 uploadDate: 2024-03-04T15:41 filename: SAP_001.pdf size: 235057 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-07 uploadDate: 2024-03-04T16:34 filename: ICF_002.pdf size: 788437 hasResults: False
nctId: NCT06324968 id: 22-AOIP-01 briefTitle: Ro60 Expression in Macrophages in Sjogren's Disease acronym: RoMioSS overallStatus: RECRUITING date: 2024-02-09 date: 2025-02-09 date: 2026-02-09 date: 2024-03-22 date: 2024-03-22 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Context: The Ro60 protein associates with YRNAs (or RNYs) to form the RoRNP complex, which regulates RNA surveillance and maturation. It is hypothesized that its impairment by nuclear penetration of the anti-Ro60 autoantibodies, would deregulate the anti-inflammatory response in monocytes/macrophages (Mo/Mp) in patients with Sjögren's disease (SD). conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 20 type: ESTIMATED name: Positive serology for anti-SSA measure: SSA/Ro60 interactions measure: The molecular and functional impact : inflammatory cytokine and chemokine profiles measure: The molecular and functional impact : cell apoptosis/survival and cellular polarization measure: The molecular and functional impact : clinical and biochemical phenotypes of CD14+ monocytes/macrophages sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Nice status: RECRUITING city: Nice state: Alpes-Mritimes zip: 06000 country: France name: Nihal MARTIS, MD, MSc role: CONTACT phone: 4 92035444 phoneExt: +33 email: martis.n@chu-nice.fr lat: 43.70313 lon: 7.26608 hasResults: False
nctId: NCT06324955 id: IRB-P00042507 briefTitle: Language During Inhalational Induction overallStatus: NOT_YET_RECRUITING date: 2024-03-11 date: 2024-07-01 date: 2025-03-11 date: 2024-03-22 date: 2024-03-22 name: Boston Children's Hospital class: OTHER briefSummary: The aim of this study is to compare the impact of common (standard of care) language vs positive language used by clinicians during inhalational induction of anesthesia on anxiety and negative behaviors in children. This is a prospective randomized parallel group trial. Patients will be randomized 1:1 to the common/standard language group or the positive language group. conditions: Emergence Delirium conditions: Anesthesia; Adverse Effect studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 128 type: ESTIMATED name: Standard/common language during induction name: Positive language during induction measure: Induction compliance measure: Length of induction measure: Verbal refusal of mask sex: ALL minimumAge: 5 Years maximumAge: 10 Years stdAges: CHILD facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: John Fiadjoe, MD role: CONTACT email: john.fiadjoe@childrens.harvard.edu name: Rachel Bernier, MPH role: CONTACT phone: 857-218-5348 email: rachel.bernier@childrens.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06324942 id: REB24-0349 briefTitle: Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section. overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-12 date: 2024-03-22 date: 2024-03-22 name: University of Calgary class: OTHER briefSummary: The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital. conditions: Cesarean Section Complications conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg measure: Post operative Pain measure: Time to first request for rescue analgesia in hours measure: Post operative Opioid use measure: Time from surgery to discharge from hospital sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Calgary city: Calgary state: Alberta zip: T2N 2T9 country: Canada lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06324929 id: HSR220448 id: R61AA030581-01 type: NIH link: https://reporter.nih.gov/quickSearch/R61AA030581-01 briefTitle: Optimizing a Digital AEP Risk Intervention With Native Women and Communities Aim 1 acronym: CARRII Native overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-09 date: 2025-03-31 date: 2024-03-22 date: 2024-03-27 name: University of Virginia class: OTHER name: University of Minnesota name: Missouri Breaks Industries Research, Inc. name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: The purpose of this aim of the ovedrall study is to gather information to inform the development of a digital app that can be used on any platform (smartphone, tablet, computer) for Native American women to help them avoid a pregnancy affected by alcohol. conditions: Alcohol Exposed Pregnancy conditions: Unplanned Pregnancies conditions: Alcohol Use, Unspecified conditions: Contraception Use conditions: Sexual Behavior studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Mixed methods research during Aim 1 will include 4 different components. They are:
4. Conduct User Testing of existing CARRII and candidate components with Think-Aloud methods among 20 Native women. primaryPurpose: OTHER masking: NONE count: 300 type: ESTIMATED name: Survey measure: Determine the characteristics of and rate of Native women eligible for, and interested in the CARRII intervention. sex: FEMALE minimumAge: 18 Years maximumAge: 44 Years stdAges: ADULT facility: University of Virginia Fontaine Research Park city: Charlottesville state: Virginia zip: 22908 country: United States name: Karen Ingersoll, PhD role: CONTACT phone: 804-651-6929 email: kes7a@uvahealth.org lat: 38.02931 lon: -78.47668 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-01-24 uploadDate: 2024-03-22T09:41 filename: Prot_SAP_000.pdf size: 558452 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-02 uploadDate: 2024-03-22T09:41 filename: ICF_001.pdf size: 242257 hasResults: False
nctId: NCT06324916 id: vascularized fibular graft briefTitle: Donor Site Morbidity After Free Vascularized Fibular Graft overallStatus: RECRUITING date: 2024-01-10 date: 2026-01-10 date: 2026-12-30 date: 2024-03-22 date: 2024-03-22 name: Assiut University class: OTHER briefSummary: This study was carried out at Assiut University to Asses the long-term donor site morbidity following free vascularized fibular transfer because there is a limited information regarding the long-term donor morbidity of this type of flap. conditions: Osteosarcoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20 type: ESTIMATED name: Xray measure: Donor site morbidity in contrast with surgery benifits this will be measured by point evaluation system sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut university status: RECRUITING city: Assiut country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06324903 id: echo cath CHD briefTitle: Role of Echocardiography in Optimization of Cardiac Catheterization in Children With Congenital Heart Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04 date: 2025-10-30 date: 2024-03-22 date: 2024-03-22 name: Assiut University class: OTHER briefSummary: Delineate and evaluate the role of echocardiography in children with congenital heart disease undergoing cardiac catheterization in the pediatric cardiology unit of Assiut university hospitals.
4. To facilitate standardized longitudinal monitoring after interventions to evaluate outcomes and detect complications. conditions: Echocardiography studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 67 type: ESTIMATED name: echocardiography and percutaneous cardiac catheterization measure: congenital heart defect dimensions in mm, measure: pressure gradient in mmHg across valve measure: cardiac function by measuring fraction shortening (FS) % in percent measure: cardiac function TAPSV in cm/sec sex: ALL minimumAge: 1 Month maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06324890 id: 20240225 briefTitle: PET-CT Imaging Features of Meibomian Glands overallStatus: RECRUITING date: 2024-01-31 date: 2024-12-31 date: 2024-12-31 date: 2024-03-22 date: 2024-03-22 name: Zhongnan Hospital class: OTHER briefSummary: Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively conditions: MGD-Meibomian Gland Dysfunction conditions: Positron-Emission Tomography conditions: Dry Eye studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED measure: Lacrimal river height measure: Tear break-up time measure: Tear-film lipid layer thickness measure: Meibomian glands two-dimensional digital infrared images sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongnan Hospital of Wuhan University status: RECRUITING city: Wuhan state: Hubei zip: 430071 country: China name: Min Ke, Doctor role: CONTACT phone: +86-18672395959 email: keminyk@163.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06324877 id: HREC/24/QCHQ/106030 briefTitle: Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside acronym: ATNAD overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-10-30 date: 2025-10-30 date: 2024-03-22 date: 2024-04-18 name: The University of Queensland class: OTHER briefSummary: Study design: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain. Study population: 6-10 patients with Ataxia-Telangiectasia. Dose: Nicotinamide riboside 25 mg/kg/day in 3 equal divided doses.
Primary endpoint: Scales for assessment and rating of ataxia (SARA), and International Cooperative Ataxia Rating Scale (ICARS). Improvement of at least ½ standard deviation in key clinical scales which includes either; a) significant improvement in total combined scores from the SARA and ICARS scales, and /or b) significant improvements any aspects of the SARA and ICARS scales individually, especially pertaining to; Postural and gait improvements, Improved syllable speed and articulation, Improved fine motor skills.
Secondary endpoints: Serum analysis of neurofilament light chain (Nfl), Type 1 Interferon (INFs) epigenetic signature conditions: Ataxia Telangiectasia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 1. Primary objective: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain.
* Type 1 Interferon (INFs) epigenetic signature specifically the cGAS-STING pathway. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 10 type: ESTIMATED name: Nicotinamide riboside measure: Scales for assessment and rating of ataxia measure: International Cooperative Ataxia Rating Scale measure: Serum analysis of neurofilament light chain measure: Type 1 Interferon epigenetic signature measure: Quality of Life Measures sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Queensland Children's Hospital city: Brisbane state: Queensland zip: 4101 country: Australia name: David Coman, MBBS FRACP role: CONTACT phone: +610730681111 email: david.coman@health.qld.gov.au lat: -27.46794 lon: 153.02809 hasResults: False
nctId: NCT06324864 id: 2024-00212 briefTitle: START NOW Adapted: Culturally Adapted Version of START NOW overallStatus: RECRUITING date: 2024-03-13 date: 2026-03 date: 2026-03 date: 2024-03-22 date: 2024-03-22 name: Prof. Christina Stadler class: NETWORK briefSummary: The goal of this clinical trial is to test the effectiveness of the culturally adapted skills-training START NOW in youth migrant populations. The main question it aims to answer is: Is the culturally adapted skills training START NOW more effective than treatment as usual (TAU) in reducing mental health problems in migrants? Participants will be randomly assigned to the intervention group receiving the skills training START NOW Adapted or the control group receiving TAU. Researchers will compare both groups to see if START NOW Adapted is more effective than TAU in reducing mental health problems in migrants. conditions: Depression conditions: Depression/Anxiety conditions: Anxiety conditions: Adolescent conditions: Emotion Recognition conditions: Mental Health conditions: Resilience,Psychological conditions: Refugee Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: START NOW Adapted measure: Change from baseline in symptoms of depression and anxiety at the end of the intervention measure: Change from baseline in symptoms of depression and anxiety at follow-up measure: Change from baseline in self-reported perceived stress at follow-up measure: Change from baseline in self-reported social-ecological resilience at the end of the intervention measure: Change from baseline in self-reported perceived stress at the end of the intervention measure: Change from baseline in self-reported social-ecological resilience at follow-up measure: Change from baseline in facial emotion recognition at the end of the intervention measure: Change from baseline in facial emotion recognition at follow-up sex: ALL minimumAge: 15 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University Psychiatric Clinics Basel status: RECRUITING city: Basel state: Basel-Stadt zip: 4002 country: Switzerland name: Donja Brunner, PhD role: CONTACT phone: +410613258031 email: donja.brunner@unibas.ch name: Janine Bacher, MSc role: CONTACT phone: +410613258048 email: janine.bacher@upk.ch name: Donja Brunner, PhD role: PRINCIPAL_INVESTIGATOR lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06324851 id: DROVZOEFFIPREP briefTitle: The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation overallStatus: COMPLETED date: 2023-01-01 date: 2023-08-01 date: 2024-03-01 date: 2024-03-22 date: 2024-04-08 name: University of Palermo class: OTHER name: University of Roma La Sapienza briefSummary: The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Drospirenone/Estetrol or Nomegestrol Acetate/Estradiol or Ethinylestradiol/Dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy. conditions: Endometrial Polyp conditions: Endometrial Diseases studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ACTUAL name: Drospirenone / Estetrol name: Nomegestrol Acetate / Estradiol name: Ethinylestradiol / Dienogest measure: Quality of endometrial preparation sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Andrea Etrusco city: Palermo zip: 90123 country: Italy lat: 38.13205 lon: 13.33561 facility: Marco Monti city: Rome zip: 00161 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06324838 id: 248-2021-NQ briefTitle: Extended Mesenteric Resection in Ileocecal Crohn's Disease. acronym: EXCEED overallStatus: NOT_YET_RECRUITING date: 2025-01 date: 2028-12 date: 2029-06 date: 2024-03-22 date: 2024-04-04 name: Odense University Hospital class: OTHER briefSummary: The EXCEED project aims to study the role of the mesentery in disease recurrence in Crohn's disease (CD), as evidence suggests that including the mesentery when doing ileocecal resections can significantly reduce recurrence rates. The EXCEED study is a blinded randomised clinical trial with 204 participants having ileocecal Crohn's disease requiring resection. Participants will undergo either "standard" mesocolic sparing resection or extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site. The primary endpoint is endoscopic recurrence 12 months postoperatively.
Through this study, we seek to understand the mesentery's role in Crohn's disease recurrence and identify effective non-invasive methods for postoperative monitoring. conditions: Crohn's Disease of Terminal Ileum studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Blinded multicenter randomized controlled clinical trial (RCT). primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: This randomized controlled trial will incorporate blinding procedures, with the understanding that due to the nature of this interventional surgical study, the operating surgeon cannot be blinded. However, rigorous measures will be implemented to ensure blinding of both patients and all other participants involved in patient treatment. The description of the surgery within the patient chart will follow a standardized format, with the exception of the resection details. Where the two treatment methods diverge, a predefined, standardized text referencing the study will be inserted. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 204 type: ESTIMATED name: Standard laparoscopic ileocecal resection name: Extended laparoscopic ileocecal resection measure: Endoscopic recurrence measure: Early endoscopic recurrence measure: Clinical signs of recurrence / morbidity. measure: Difference in disease severity measure: Patient reported outcome 1 measure: Patient reported outcome 2 measure: Reoperations measure: Perioperative complications measure: Cost of treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06324825 id: 2022CR64 briefTitle: Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial overallStatus: RECRUITING date: 2022-10-24 date: 2024-12-31 date: 2024-12-31 date: 2024-03-22 date: 2024-03-22 name: Peking University First Hospital class: OTHER briefSummary: Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule. conditions: Atrophic Gastritis With Low-grade Intraepithelial Neoplasia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 144 type: ESTIMATED name: Fuzhegn Nizeng Decoction name: Moluodan granules measure: Recovery rate of Low-grade Intraepithelial Neoplasia measure: 7-point Global Overall Symptom Scale measure: Adverse event rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University First Hospital status: RECRUITING city: Beijing state: Beijing zip: 100034 country: China name: Xuezhi Zhang, Doctor role: CONTACT phone: +861083572634 email: zhang.xuezhi@263.net lat: 39.9075 lon: 116.39723 hasResults: False